Medical Equipment

Ovarian Cancer Diagnostics Market Growth Forecast With Analysis Of Industry Progress Through 2030

May 15, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Increase In Market Value Is Predicted For The Ovarian Cancer Diagnostics Market During The 2026–2030 Period?

The ovarian cancer diagnostics market size has shown significant expansion in recent years. This market is anticipated to grow from $2.9 billion in 2025 to $3.11 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.4%. The historical increase in this market can be attributed to several factors, including the rising incidence of ovarian cancer, increased awareness of women’s health concerns, the development of diagnostic laboratory infrastructure, a surge in the use of imaging and biopsy procedures, and the availability of cancer screening programs.

The ovarian cancer diagnostics market is projected to experience substantial expansion over the upcoming years. By 2030, its size is anticipated to reach $4.2 billion, demonstrating a compound annual growth rate (CAGR) of 7.7%. This projected growth is driven by several factors, including escalating investments in precision oncology, a heightened demand for the early detection of cancer, the proliferation of AI-driven diagnostic platforms, an intensifying emphasis on individualized treatment strategies, and a surge in research funding dedicated to women’s cancers. Key trends expected during this period encompass the wider adoption of biomarker-based diagnostic tests, an increase in the utilization of advanced imaging techniques, the expanding incorporation of AI in cancer detection, the broadening of early screening initiatives, and a sharpened focus on personalized oncology diagnostics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12022&type=smp

What Important Drivers Are Powering The Ovarian Cancer Diagnostics Market Growth?

The increasing prevalence of gynecological cancer is anticipated to propel the expansion of the ovarian cancer diagnosis market moving forward. Gynecological cancer encompasses any cancer that develops within a woman’s reproductive organs. Ovarian cancer diagnosis drugs are instrumental in reducing the incidence of gynecological cancer by effectively treating and managing the disease, preventing its recurrence, and enhancing patient outcomes through the application of various therapies. For instance, in October 2025, Cancer Australia, an Australia-based government agency, reported that roughly 6,963 new cases of gynecological cancer were diagnosed in Australia in 2024. Hence, the significant occurrence of gynecological cancer is a key factor driving the growth of the ovarian cancer diagnosis market.

Which Segment-Based Categories Are Covered In The Ovarian Cancer Diagnostics Market?

The ovarian cancer diagnostics market covered in this report is segmented –

1) By Product Type: Instruments, Kits, Reagents

2) By Diagnosis Type: Biopsy, Blood Test, Imaging, Other Diagnosis Types

3) By Cancer Type: Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor

4) By End User: Cancer Diagnostic Centers, Hospital Laboratories

Subsegments:

1) By Instruments: Imaging Systems, Biopsy Devices, Molecular Diagnostic Instruments

2) By Kits: Diagnostic Test Kits, Screening Kits

3) By Reagents: Antibodies, Enzymes, Assay Reagents

Which Trends Are Shaping The Ovarian Cancer Diagnostics Market Landscape?

Leading companies operating in the ovarian cancer diagnostics market are forming partnerships to develop new products and strengthen their positions. Collaborations within the ovarian cancer diagnostics market boost research, development, and commercialization efforts by utilizing the expertise, resources, and networks of various entities. For instance, in August 2023, ImmunoGen Inc., a US-based biotechnology company, partnered with Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, to develop and commercialize ELAHERE (mirvetuximab soravtansine-gynx) in Japan. ImmunoGen will receive upfront and milestone payments, along with double-digit royalties, while Takeda gains exclusive rights to develop and commercialize ELAHERE in Japan, reinforcing the commitment to bring this biomarker-directed ADC to patients with Folate Receptor Alpha (FRa)-Positive, Platinum-Resistant Ovarian Cancer in the Japanese market. This partnership helps address an unmet need for individuals with platinum-resistant ovarian cancer and reinforces a shared commitment to advancing cancer treatment options globally.

Which Firms Are Competing In The Ovarian Cancer Diagnostics Market?

Major companies operating in the ovarian cancer diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Sysmex Corporation, Bio-rad Laboratories Inc., Qiagen N.V., Natera Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health, Luminex Corporation, NanoString Technologies Inc., Siemens Healthcare Private Limited, Menarini Silicon Biosystems S.p.A., Precipio Inc., Angle plc

Access The Complete Ovarian Cancer Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/ovarian-cancer-diagnostics-global-market-report

Which Region Has The Strongest Presence In The Ovarian Cancer Diagnostics Market?

North America was the largest region in the ovarian cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ovarian cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Ovarian Cancer Diagnostics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/report/ovarian-cancer-diagnostics-global-market-report

Browse Through More Reports Similar to the Global Ovarian Cancer Diagnostics Market 2026, By The Business Research Company

Next Generation Gynecological Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-gynecological-cancer-diagnostics-global-market-report

Ovarian Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/ovarian-cancer-drugs-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795